Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL

Background: T lymphocyte collection through leukapheresis is an essential step for chimeric antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily pretreated patients who suffer from rapid progressive disease and receive T cell impairing medication. Methods: A total o...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Felix Korell, Sascha Laier, Sandra Sauer, Kaya Veelken, Hannah Hennemann, Maria-Luisa Schubert, Tim Sauer, Petra Pavel, Carsten Mueller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2020-05-01
Sarja:	Cells
Aiheet:	CAR T cell apheresis lymphocyte collection CD3 positive lymphocytes
Linkit:	https://www.mdpi.com/2073-4409/9/5/1225
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!